atHeart Medical

Executive Summary

atHeart Medical is a Swiss medical device company focused on developing minimally invasive transcatheter solutions for structural heart diseases, particularly atrial septal defects (ASDs). Its lead product, the reSept™ ASD Occluder, features a unique metal-free frame designed to reduce long-term complications and preserve future interventional options. Founded in 2016 and headquartered in Lausanne, the company operates in the cardiovascular and medical devices categories. With a strong emphasis on innovation and patient outcomes, atHeart Medical aims to address the limitations of conventional occluders, such as risk of erosion, thrombogenicity, and interference with future procedures. The company is privately held and has not disclosed fundraising or valuation details. Although still in a relatively early stage, atHeart Medical's differentiated technology positions it as a potential disruptor in the ASD closure market, which is currently dominated by metallic devices. The company's success hinges on regulatory clearances and clinical adoption, with a clear path toward commercialization pending approvals.

Upcoming Catalysts (preview)

• Q3 2026CE Mark Approval for reSept™ ASD Occluder70% success
• Q4 2026FDA Investigational Device Exemption (IDE) Approval for US Pivotal Trial60% success
• Q2 2026Strategic Partnership or Distribution Agreement for European Launch75% success